TITLE

Associations of Preexisting Depression and Anxiety With Hospitalization in Patients With Cardiovascular Disease

AUTHOR(S)
CHAMBERLAIN, ALANNA M.; VICKERS, KRISTIN S.; COLLIGAN, ROBERT C.; WESTON, SUSAN A.; RUMMANS, TERESA A.; ROGER, VÉRONIQUE L.
PUB. DATE
November 2011
SOURCE
Mayo Clinic Proceedings;Nov2011, Vol. 86 Issue 11, p1056
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To determine the risk of hospitalization and death in relation to preexisting depression and anxiety among patients with cardiovascular disease (CVD). PATIENTS AND METHODS: The cohort consisted of 799 Olmsted County, MN, residents diagnosed with CVD (myocardial infarction or heart failure) from January 1, 1979, to December 31, 2009, who completed a Minnesota Multiphasic Personality Inventory (MMPI) prior to their event. The MMPI was used to identify depression and anxiety, and participants were followed up for hospitalizations and death during an average of 6.2 years. RESULTS: Depression and anxiety were identified in 282 (35%) and 210 (26%) participants, respectively. After adjustment, depression and anxiety were independently associated with a 28% (95% confidence interval [CI], 8%-51%) and 26% (95% CI, 3%-53%) increased risk of being hospitalized, respectively. Depression also conferred an increased risk of all-cause mortality of similar magnitude, whereas the hazard ratio for anxiety was not statistically significant. The combined occurrence of depression and anxiety led to a 35% (95% CI, 8%-71%) increase in the risk of hospitalizations. CONCLUSION: Among patients with CVD, both preexisting depression and anxiety, occurring on average 17 years before the CVD event, independently predict hospitalizations. In addition, the 2 conditions may act synergistically on increasing health care utilization in patients with CVD.
ACCESSION #
67320952

 

Related Articles

  • Acute myocardial infarction and heart failure in acute stroke patients: frequency and influence on clinical outcome. Micheli, Sara; Agnelli, Giancarlo; Caso, Valeria; Alberti, Andrea; Palmerini, Francesco; Venti, Michele; Paciaroni, Maurizio // Journal of Neurology;Jan2012, Vol. 259 Issue 1, p106 

    In patients admitted for acute stroke, the clinical burden of acute myocardial infarction (AMI) and acute heart failure (AHF) is unclear. In these patients we evaluated: (1) the prevalence of AMI and AHF; (2) the effect of AMI and/or AHF on mortality at 3 months; (3) the risk factors for AMI...

  • Early β-blockade in acute myocardial infarction. Tereschenko, Sergey N.; Zhirov, Igor V. // Hot Topics in Cardiology;2013, Issue 33, p7 

    Current guidelines recommend beginning treatment with β-blockers within the first 24 h following an ST-elevation myocardial infarction (STEMI) for those patients who do not have signs of heart failure or low cardiac output state and who do not have risk factors for cardiogenic shock-ie, >70...

  • Left atrial strain is related to adverse events in patients after acute myocardial infarction treated with primary percutaneous coronary intervention. Antoni, M. Louisa; Brinke, Ellen A. ten; Atary, Jael Z.; Marsan, Nina Ajmone; Holman, Eduard R.; Schalij, Martin J.; Bax, Jeroen J.; Delgado, Victoria // Heart;Aug2011, Vol. 97 Issue 16, p1332 

    Background Left atrial (LA) maximal volume is of prognostic value in patients after acute myocardial infarction (AMI). Recently, LA mechanical function and LA strain have been introduced as alternative methods to assess LA performance more accurately. Objective To evaluate the relation between...

  • Increased CV risk with rosiglitazone but not pioglitazone.  // Reactions Weekly;10/31/2009, Issue 1276, p2 

    The article discusses research which showed that rosiglitazone exposure is associated with an increased risk of cardiovascular (CV) events unlike pioglitzone exposure. It references a study by F. T. Shaya and colleagues, published in the "P&T" journal. The results confirm a previous Canadian...

  • Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Hjalmarson, Å. // Basic Research in Cardiology;Nov2000 Supplement 1, Vol. 95, pI41 

    Beta-blockers have several beneficial cardiovascular effects in patients with hypertension, angina pectoris, myocardial infarction, and congestive heart failure. In patients with myocardial infarction and congestive heart failure some beta-blockers have been found to reduce mortality and...

  • Hamburg meeting – April, 1. 2000.  // Basic Research in Cardiology;Nov2000 Supplement 1, Vol. 95, pI1 

    The article discusses mortality due to cardiovascular disease in both men and women in the developed countries of the world. In many of these countries the mortality rate is starting to fall significantly. There are probably many reasons for this welcome decline in the mortality rates from...

  • Measuring Comorbidity in Cardiovascular Research: A Systematic Review. Buck, Harleah G.; Akbar, Jabar A.; Zhang, Sarah Jingying; Prvu Bettger, Janet A. // Nursing Research & Practice;2013, p1 

    Background. Everything known about the roles, relationships, and repercussions of comorbidity in cardiovascular disease is shaped by how comorbidity is currently measured. Objectives. To critically examine how comorbidity is measured in randomized controlled trials or clinical trials and...

  • Cardiovascular highlights from non-cardiology journals. Lindsay, Alistair C. // Heart;Dec2011, Vol. 97 Issue 23, p1990 

    The article offers information on research related to cardiovascular diseases that was published in various journals. One of them was related to the increased use of platelet function testing and the risk of ischaemic events following percutaneous coronary intervention. Kane G.C. in a study...

  • Cardiovascular disease. Gore, Joel M.; Dalen, James E. // JAMA: Journal of the American Medical Association;6/19/96, Vol. 275 Issue 23, p1797 

    Focuses on advances in cardiovascular disease. Increased prevalence of chronic congestive heart failure which is due, partly, to improved survival resulting from medical therapy; Study of coronary artery revascularization; Cost of thrombolytic therapy for acute myocardial infarction; Efficacy...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics